Please login to the form below
ICU Medical
This page shows the latest ICU Medical news and features for those working in and with pharma, biotech and healthcare.
Pfizer to shut down two UK manufacturing sites
Pfizer has already sold off Hospira's infusion therapy business unit, bringing in $600m in cash and $400m in stock from buyer ICU Medical as it looks to focus on pharmaceuticals.
Latest news
-
Pfizer to sell off Hospira's infusions business - and its New York HQ
The business unit - which produces pumps, infusion solutions and other devices - is being bought by ICU Medical, a specialist in infusion therapy. ... The ICU Medical deal is expected to close in the first quarter of 2017, said the two companies in a
Pfizer to sell off Hospira's infusions business - and its New York HQ
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
$223m royalties. $142m. 1.6. Cardiovascular 2016. China Medical System. Plendil China. ... 1, 120. Hospira / Pfizer (US). ICU Medical (US). Asset Acquisition.
Deal Watch October 2016
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- US demand for COVID-19 antibody treatments rising fast
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
- WHO to test three more potential COVID-19 treatments
- Langland promotes Jake Davis to managing partner
- Patient diversity in clinical trials needs to be centre stage
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
